Current challenges in implementing cell-derived influenza vaccines: Implications for production and regulation, July 2007, NIBSC, Potters Bar, UK

Vaccine

Volumn 27, Issue 22, 2009, Pages 2907-2913

  Minor, Philip D ^a   Engelhardt, Othmar G ^a   Wood, John M ^a   Robertson, James S ^a   Blayer, Simone ^k   Colegate, Tony ^g,m   Fabry, Luc ^f   Heldens, Jacco G M ^j   Kino, Yoichiro ^h   Kistner, Otfried ^b   Kompier, Ronald ^c   Makizumi, Keiichi ^h   Medema, Jeroen ^o   Mimori, Shigetaka ^e   Ryan, David ^d   Schwartz, Richard ⁱ   Smith, Jonathan S B ⁿ   Sugawara, Keishin ^h   Trusheim, Heidi ^k   Tsai, Theodore F ^l   Krause, Ryoko ^g   more..

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b BAXTER INNOVATIONS GMBH   (Austria)

^c CRUCELL HOLLAND BV   (Netherlands)

^d CSL LIMITED   (Australia)

^e DENKA COMPANY LIMITED   (Japan)

^f GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^g International Federation of Pharmaceutical Manufacturers and Associations   (Switzerland)

^h KAKETSUKEN   (Japan)

ⁱ MEDIMMUNE   (United States)

^j Nobilon International BV   (Netherlands)

^k GSK Marburg Vaccines and Diagnostics   (Germany)

^l NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^m Novartis Vaccines and Diagnostics   (United Kingdom)

ⁿ SANOFI PASTEUR   (France)

^o Solvay Pharmaceuticals Inc   (Netherlands)

more..

Author keywords

Cell substrates; Influenza vaccine manufacture; Reagent development; Strain selection

Indexed keywords

INFLUENZA VACCINE; REAGENT;

CALIBRATION; CELL CULTURE; CELL LINE; CONFERENCE PAPER; DISEASE SURVEILLANCE; DRUG POTENCY; EGG; HUMAN; IMMUNODIFFUSION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; VACCINE PRODUCTION; VIRUS STRAIN;

DRUG APPROVAL; GREAT BRITAIN; HUMANS; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE; REASSORTANT VIRUSES; VIRUS CULTIVATION;

EID: 67349117322     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.064     Document Type: Conference Paper

References (25)

1. Roger G.N., Daniels R.S., Skehel J.J., Wiley D.C., Wang X.F., Higa H.H., et al. Host-mediated selection of influenza virus receptor variants. Sialic acid-alpha 2,6Gal-specific clones of A/duck/Ukraine/1/63 revert to sialic acid-alpha 2,3Gal-specific wild type in ovo. J Biol Chem 260 12 (1985) 7362-7367
2. Robertson J.S., Naeve C.W., Webster R.G., Bootman J.S., Newman R., and Schild G.C. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 143 1 (1985) 166-174
3. Katz J.M., Naeve C.W., and Webster R.G. Host cell-mediated variation in H3N2 influenza viruses. Virology 156 2 (1987) 386-395
4. Robertson J.S., Bootman J.S., Newman R., Oxford J.S., Daniels R.S., Webster R.G., et al. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A (H1N1) virus. Virology 160 1 (1987) 31-37
5. Kistner O., Barrett P.N., Mundt W., Reiter M., Schober-Bendixen S., and Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16 (1998) 960-968
6. Palache A.M., Scheepers H.S.J., de Regt V., van Ewijk P., Baljet M., Brands R., et al. Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated influenza subunit vaccine A meta-analysis of clinical studies. Dev Biol Stand 98 (1999) 115-125
7. Pau M.G., Ophorst C., Koldijk M.H., Schouten G., Mehtali M., and Uytdehaag F. The human cell line PER C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19 (2001) 2716-2721
8. Recommended composition of influenza virus vaccines for use in the 2008-2009 influenza season. Weekly epidemiological record 2008;83:81-87.
9. WHO. A description of the process of seasonal and H5N1 influenza vaccine virus selection and development (http://www.who.int/csr/disease/avian_influenza/Fluvaccvirusselection.pd f).
10. Baez M., Palese P., and Kilbourne E.D. Gene composition of high-yielding influenza vaccine strains obtained by recombination. J Infect Dis 141 (1980) 362-365
11. Wood J.M., Mumford J., Schild G.C., Webster R.G., and Nicholson K.G. Single-radial-immunodiffusion potency tests of inactivated influenza vaccines for use in man and animals. Dev Biol Stand 64 (1986) 169-177
12. Oxford J.S., Corcoran T., and Hugentobler A.L. Quantitative analysis of the protein composition of influenza A and B viruses using high resolution SDS polyacrylamide gels. J Biol Stand 9 (1981) 483-491
13. Wood J.M., and Levandowski R.A. The influenza vaccine licensing process. Vaccine 21 (2003) 1786-1788
14. Update: Influenza activity - United States and worldwide, 2003-04 season, and composition of the 2004-05 influenza vaccine. Morbidity and Mortality Weekly Report 2004;53(25):547-52.
15. WHO. Recommendations for the production and control of influenza vaccine (inactivated). WHO Technical Report Series 2005;927:99-134.
16. Bardia N., and Bae J.H. Influenza vaccines: recent advances in production technologies. Appl Microbiol Biotechnol. 67 (2005) 299-305
17. Gregersen J.-P. A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines. Vaccine 26 (2008) 3297-3304
18. EMEA. Cell culture inactivated influenza vaccines. Annex to note for guidance on harmonization of requirements for influenza vaccines (CPMP/BWP/214/96). 2002;CPMP/BWP/2490/00 http://www.emea.europa.eu/humandocs/PDFs/EPAR/optaflu/H-758-en6.pdf.
19. Meguro H., Bryant J.D., Torrence A.E., and Wright P.F. Canine kidney cell line for isolation of respiratory viruses. J Clin Microbiol 9 (1979) 175-179
20. Trusheim H., Roth B., Wilms R., Jung S., Muth R., Eggers M., et al. The MDCK 33016-PF cell line is not only suitable for the production of cell based influenza vaccine but also an ideal substrate for influenza virus isolation. Options for the Control of Influenza Conference VI Toronto (2007)
21. Reina J., Fernandez-Bacon V., Blanco I., and Munar M. Comparison of Madin-Darby canine kidney cells (MDCK) with a green monkey continuous cell line (Vero) and human lung embryonated cells (MRC-5) in the isolation of influenza A virus from nasopharyngeal aspirates by shell vial culture. J Clin Microbiol 35 (1997) 1900-1901
22. Kistner O., Barrett P.N., Mundt W., Reiter M., Schober-Bendixen S., Eder G., et al. Development of a Vero cell-derived influenza whole virus vaccine. Dev Biol Stand 98 (1999) 101-110
23. Neumann G., and Kawaoka Y. Generation of influenza A virus from cloned cDNAs-historical perspective and outlook for the new millennium. Rev Med Virol 12 (2002) 13-30
24. Nicolson C., Major D., Wood J.M., and Robertson J.S. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23 (2005) 2943-2952
25. Wood J.M., Dunleavy U., Newman R.W., Riley A.M., Robertson J.S., and Minor P.D. The influence of the host cell on standardisation of influenza vaccine potency. Dev Biol Stand 98 (1999) 183-188